Schroder Investment Management Group Decreases Stock Position in Dyne Therapeutics, Inc. $DYN

Schroder Investment Management Group trimmed its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 15.3% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 205,626 shares of the company’s stock after selling 37,199 shares during the quarter. Schroder Investment Management Group’s holdings in Dyne Therapeutics were worth $1,958,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in DYN. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Dyne Therapeutics by 22.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company’s stock worth $201,000 after acquiring an additional 3,496 shares during the last quarter. XTX Topco Ltd purchased a new stake in Dyne Therapeutics in the 1st quarter worth about $330,000. Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 10.5% in the first quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company’s stock worth $77,470,000 after purchasing an additional 702,418 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Dyne Therapeutics by 347.7% during the first quarter. Deutsche Bank AG now owns 317,664 shares of the company’s stock valued at $3,323,000 after buying an additional 246,703 shares during the period. Finally, Swiss National Bank boosted its position in shares of Dyne Therapeutics by 8.9% during the first quarter. Swiss National Bank now owns 118,300 shares of the company’s stock valued at $1,237,000 after buying an additional 9,700 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $20.28 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $29.72. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The stock has a fifty day simple moving average of $18.46 and a two-hundred day simple moving average of $14.00. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of -5.54 and a beta of 1.30.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. On average, analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the topic of several recent analyst reports. Royal Bank Of Canada increased their price target on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Evercore ISI reiterated an “outperform” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. Raymond James Financial raised shares of Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $31.00 to $35.00 in a research note on Monday, August 25th. Finally, Oppenheimer cut their price target on shares of Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating on the stock in a report on Wednesday, November 12th. Four research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $35.47.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.